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Summary-The combined effect of the chemotherapeutic agent ICRF-159 and
irradiation were evaluated using the Lewis lung tumour (LL). At a daily dose of
25 mg/kg, ICOF given alone prevented the progressive growth of LL. Daily pretreat-
ment also potentiated the effects ofradiation(600rad) ontumourgrowth, providedthe
pretreatment kinetics of the tumour permitted a response to radiation alone. Single
acute doses ofthe drug failed to alter the growth ofLL, andwhencombined withradia-
tion failed to enhance the radiation effect. Fractionation of the drug (25 mg/kg;
4 doses at 3h intervals) before irradiation, however, results in immediate effects on
tumour growth which are more than additive. The results suggest that a low dose
of ICRF-159 for extended periods is more effective in enhancing radiotherapy than a
high dose provided acutely.
THE cancer-chemotherapeutic agent
ICRF-159 [(i)1,2-di (3,5-dioxopiperazine-
1-yl) propane] belongs to a family of
bisdioxopiperazines which has been repor-
ted as cytotoxic during a brief period of
the cell cycle (Hellmann & Field, 1970).
Using PHA-stimulated human lympho-
cytes (Sharpe et al., 1970) and erythroid
maturation in C57BL mice (Blackett &
Adams, 1972), ICRF-159 was found to
prevent the entrance of cells into mitosis
if the cells were exposed during the pre-
mitotic and early mitotic (G2/M) phases
of the cell cycle. Furthermore, drug cyto-
toxicity has been reported to be schedule-
dependent rather than dose-dependent
(Hallowes et al., 1974; Stephens & Creigh-
ton, 1974). Taylor & Bleehen (1977a) have
recently reported that prolonged exposure
to low concentrations of ICRF-159 are
more lethal to the EMT6 tumour-cell line
than high concentrations. This dose res-
ponse has been attributed to the cyto-
static action ofthe drug at high concentra-
tions.
In addition to cytotoxicity, ICRF-159
has been reported to function as (1) an
antimetastatic agent (Hellman & Burrage,
1969; Salsbury et at., 1970) and (2) as a
radiopotentiator (Hellmann & Murken,
1974; Norpoth et al., 1974; Peters, 1976;
Ryall et al., 1974). Both the antimetastatic
and radiopotentiating activities of ICRF-
159 have been attributed to a drug-induced
angiometamorphic effect found in studies
on the Lewis lung carcinoma (LL)
(LeServe & Hellmann, 1972; James &
Salsbury, 1974; Salsburyetal., 1974). How-
ever, Peters (1976), studying the modifying
effects of ICRF-159 on clamped tumours
suggests that improved vascularization
can not fully explain the drug's "radio-
sensitizing" action. Furthermore, Taylor
& Bleehen (1977a, b) have reported ICRF-
159 radiopotentiation in vitro, where
tumour vasculature is of no conse-
quence.
The effects of combined ICRF-159 plus
radiation on the growth of the Lewis lung
carcinoma has not been studied exten-
sively in terms of dose/time relationships.
For this reason, we have initiated such
studies to evaluate ICRF-159 potentiation
of the radiation response of LL.ICRF-159 ENHANCED RADIATION RESPONSE. I
MATERIALS AND METHODS
Tumour growth.-Male BDF1 mice ob-
tained from Jackson Laboratories (Bar
Harbor, ME) were inoculated s.c. in the back
with 106 cells of a single-cell suspension
prepared from a stock LL originally obtained
from Linda Simpson-Herren, Southern Re-
search Institute, Birmingham, Al. The LL
is routinely maintained by s.c. transplanta-
tion into BDF1 males. The mice were main-
tained under a 12 h lighting schedule, the
dark period beginning at 6 p.m., and Purina
Lab Chow and water supplied ad libitum.
Tumour volumes (2 L xW x H) were esti-
mated from measurements of length, width
and height, made sequentially during the
experiments. Experimental groups consisted
of 10 mice each.
ICRF-159.-ICRF-159 (NSC 129943) was
supplied by Dr H. B. Wood, Drug Synthesis
and Chemistry Branch, DCT, National Cancer
Institute. The drug was finely suspended in
a sterile solution of 0.5% (w/v) carboxy-
methylcellulose-saline (CMC-saline) and the
suspension stirred for 30 min before injec-
tion. ICRF-159 was injected i.p. so that the
volume of each injection was 0 01 ml/g body
wt.
Radiation.-Irradiation was performed
with a General Electric Maxitron 300. The
physical factors of X-irradiation were 275
kVcp, 20 mA, H.V.L.=1-8 mmCu, and TSD
of 31 cm. Animals were positioned in leucite
containers in such a way that the parts ofthe
animal anterior to the xyphoid process, the
femurs and the tail were shielded with lead.
Animals were irradiated to a total dose of
600 rad at a rate of 80 rad/min.
RESULTS
Effect of tumiour irradiation
With increasing tumour age, the magni-
tude ofthe LL tumour response to 600rad
decreased (Fig. 1). Three days after
irradiation of 7-day tumours, tumour
volume had regressed to 50% ofthevolume
at the time of irradiation. Thereafter,
growth was resumed at a rate approaching
that for unirradiated tumours. In contrast,
when tumours -were irradiated on Day 14
after inoculation, there was no evidence of
regression, and by 48 h after irradiation
growth was resumed. Tumours irradiated
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FiG. 1-.Theeffectof600radontumourgrowth
as a function of tumour age. *, growth
of unirradiated LL tumour; *, tumours
irradiated 7 days after tumour inoculation;
0, tumours irradiated 14days after tumour
inoculation; Oii, tumours irradiated 21 days
after tumour inoculation. Each point
represents the mean tumour volume ±s.e.
for a group of 10 animals.
at 21 days failed to respond to a dose of
600 rad X-rays.
Daily ICRF-159 treatment
Daily injections of 25 mg/kg ICRF-159,
starting 1 day after inoculation with
tumour cells, produced a significant in-
hibition of growth, first seen on Days 8-9
and continuing untilDay 14 (Fig. 2). When
drug treatment was discontinued on Day
14, tumour growth accelerated with little
delay. Daily injection of CMC-saline did
not prevent continued tumour growth.
Pretreatment of tumours with 25 mg/kg
ICRF-159/day starting on Day 1 failed
to alter the age-related tumour response
to radiation (Fig. 3). Tumours pretreated
for 7 days before irradiation, however,
showed an enhanced response to 600 rad
(see Fig. 1). With drug pretreatment,
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FIG. 2. The effect of daily ICRF-159 or
CMC-saline treatment on the growth of the
LL tumour. 0, untreated tumours; 0,
tumours treated daily through Day 14
with CMC-saline; *, tumours treated daily
through Day 14 with 25 mg/kg ICRF-159.
Each point represents the mean tumour
volume ±s.e. for a group of 10 animals.
tumour regression was nearly complete
(5.6% ofvolume at irradiation) by Day 12.
Radiation alone produced regression to
only 34% of pretreatment volume. With
combined treatment, regrowth was prompt
and mean tumour volume approached
that of drug-only treated tumours by
Day 19 (see Fig. 2). Tumours pretreated
for 14 days before irradiation failed to
respond to irradiation.
Drug-radiation treatments
Tumour bearing animals were treated
on Day 7 after inoculation with ICRF-159
doses ranging from 25 to 175 mg/kg. Acute
treatment failed to alter tumour growth
substantially (Fig. 4). Unlike daily drug
exposure, there was no evidence of regres-
sion or stabilization of tumour volume.
However, by Day 15 there was evidence of
growth retardation associated with the
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FIG. 3.-The effect of daily ICRF-159 pre-
treatment on the radiation response of the
LL tumour. 0, untreated tumours; *,
25mg/kg ICRF-159 daily before irradiation
on Day 7; -, 25 mg/kg ICRF-159 daily
before irradiation on Day 14. Each point
represents the mean tumour volume ±s.e.
for a group of 10 animals. Animals were
irradiated with 600 R.
100 mg/kg dose. Similarly, the tumours
receiving 175 mg/kg appeared slightly
larger than control for a short time.
However, there was little significant dif-
ference in size of tumours on Day 20
post inoculum between any of the groups.
Acute treatment with ICRF-159 up to 175
mg/kg had little effect on the growth rate
of tumours, when compared to daily
injections of 25 mg/kg.
After 600 rad X-rays, LL regressed
within 24 h, and continued to shrink over
the next 24 h. Regrowth was apparent
3-4 days after radiation (dashed lines,
Fig. 5). Pretreatment with ICRF-159 at
several dose levels 5 min before radiation
failed to augment the tumour response to
radiation. Onthe otherhand, pretreatment
with ICRF-159 reduced the magnitude or
duration of tumour regression after radia-
tion exposure. And those tumours treated
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FIG. 4.-The effect ofacute ICRF-159 dose on
growth of the LL tumour. 0, growth of
untreated tumours; 0, 25 mg/kg ICRF-
159; A, 50 mg/kgICRF-159; A, 100 mg/kg
ICRF-159; *, 175 mg/kg ICRF-159. Each
point represents the mean tumour volume
±s.e. for a group of 10 animals treated on
Day 7 after tumour inoculation.
with drug+radiation reinitiated growth
more rapidly than after radiation alone.
To determine whether the drug carrier
(CMC-saline) protected the tumour against
radiation, the 100 mg/kg ICRF-159 experi-
ment was repeated and a comparison was
made between the tumour response to
radiation after both ICRF-159 in CMC-
saline and CMC-saline-alone pretreat-
ments. This comparison is summarized in
Fig. 6. Pretreatment with CMC-saline
alone failed to alter the course ofradiation-
induced regression and regrowth. How-
ever, pretreatment with ICRF-159 in
CMC-saline diminished the radiation effect
much as in Fig. 5.
Fractionated ICRF-159 treatments: drug-
schedule effects on the radiation response
The tumour response to radiation after
pretreatment with 25 mg/kg ICRF-159 at
3 h intervals is presented in Fig. 7.
Tumours receiving 4 and 3 injections
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FIG. 5.-The effect of acute ICRF-159 dose
on the radiation response ofthe LL tumour.
(a) 25 mg/kg; (b) 50 mg/kg; (c) 100 mg/klg:
(d) 175 mg/kg. Dashed line redrawn from
the Day 7 600 rad radiation response curve
in Fig. 1. 0, untreated tumours; 0,
ICRF-159 5 min before 600 rad. Each point
represents the mean tumour volume ±s.e.
for a group of 10 animals treated on Day 7
after tumour-inoculation.
(total dose 100 and 75 mg/kg respectively)
before irradiation showed significantly
more radiation-induced regression of LL
than tumours receiving 1 and 2 injections
(25 and 50 mg/kg) before irradiation.
The differences between the groups receiv-
ing 3 or 4 injections and those receiving
1 or 2 injections suggest that pretreatment
drug efficacy may be related to dose level
(50-75 mg/kg) and/or total length of pro-
tracted treatment (6-9 h).
The increased efficacy of fractionated
pretreatment with ICRF-159 before radia-
tion over acutely administered drug+
radiation is seen in Fig. 8. Acute pretreat-
ment with 100 mg/kg has little effect on
the tumour response to 600 rad, and may
even "protect" againstthe radiation effect.
However, the same dose fractionated
(25 mg/kg x 4) before irradiation produced
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FIG. 6.-The effect of acute CMC-saline or
ICRF-159 pretreatment on the radiation
response of the LL tumour. 0, untreated
tumours; 0, 600 rad X-rays; *, CMC-
saline 5 min before 600 rad; A, 100 mg/kg
ICRF-159 5 min before 600 rad. Each point
represents the mean tumour volume ±s.e.
for a group of 10 animals treated on Day 7
after tumour inoculation.
a 2-fold reduction in mean tumour volume
above that obtained for 600rad alone (67%
vs 34% reduction of tumour volume at
treatment). Because neither an acute dose
of 100 mg/kg (Fig. 4) nor its fractionated
equivalent (Fig. 8) produces tumour re-
gression, the regression effects of frac-
tionated ICRF-159+radiation on tumour
growth are more than additive. Whilst
tumour regression after treatment is an
inherent characteristic of the kinetics and
histopathology ofindividual tumour types,
and therefore does not necessarily reflect
the number of cells killed (Denekamp,
1972; Kovacs et al., 1977), tumour re-
gression and the accompanying regrowth
delay, as seen in Fig. 8, demonstrate
the superiority of fractionated over acute
pretreatment with ICRF-159 before radio-
therapy.
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FIG. 7.-The effect of fractionated pretreat-
ment with ICRF-159 on the radiation
response of the LL tumour. 0, untreated
tumours; 0, 25 mg/kg ICRF-159 3 h before
600 rad; *, 25 mg/kg (3-hourly x 2) ICRF-
159 before 600 rad; A, 25 mg/kg (3-hourly
x 3) ICRF-159 before 600rad; A, 25mg/kg
(3-hourly x 4) ICRF-159 before 600 rad.
Each point represents the mean tumour
volume ±s.e. for a group of 10 animals.
Pretreatments were completed 3 h before
irradiation.
DISCUSSION
Several reports have suggested that
multiple treatments with ICRF-159 in-
hibited the growth of the LL, although
the degree of inhibition ranged from
negligible to highly effective (Hellmann &
Burrage, 1969; Salsbury, 1970; James &
Salsbury, 1974). The results in our present
studies (Figs. 2 & 3), as well as those
reported for other experimental tumours
(Hellmann & Murken, 1974; Norpoth
et al., 1974; Atherton, 1975) strongly
suggest that daily doses of ICRF-159 can
effectively prevent the growth of LL.
Furthermore, we have shown that daily
ICRF-159 pretreatment can potentiate
the effects of radiation on tumour growth.
Simpson-Herren et al. (1974) have reported
that with progressive growth of LL there
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pretreatment with ICRF-159 on the
radiation response of the LL tumour.
0, growth of untreated tumours; U,
600 radX-irradiation; O, 100mg/kgICRF-
159 5 min before 600 rad; 0, fractionated
(25 mg/kg; 3-hourly x 4) ICRF-159 pre-
treatment before 600 rad; *, fractionated
(25 mg/kg; 3-hourly x 4) ICRF-159 treat-
ment alone. Each point represents the
mean volume +s.e. for a group of 10
animals treated on Day 7 after tumour
inoculation.
is a reduction in growth fraction and
elongation of mean cycle time. Our data
therefore suggest that the LL tumour,
most sensitive to ICRF-159-induced kine-
tic and growth perturbations when com-
bined with radiation, would be a highly
proliferative tumour.
Stanley et al. (1977) have demonstrated
a tumour-size dependence on therapeutic
sensitivity ofLL, and have suggested that
a change in radiosensitivity can be attribu-
ted to a marked increase in the hypoxic
fraction, correlated with increased necrotic
and haemorrhagic areas.
Although Hellmann & Murken (1974)
have experimental evidence that ICRF-
159 potentiated radiation effects, and have
postulated that the synergism of drug and
radiation might be closely linked to the
normalization of tumour blood vessels,
reducing tumourhypoxia, from the studies
presented in Fig. 3, daily ICRF-159 pre-
treatment before irradiation, whilst en-
hancing the radiation response of Day-7
tumours, failed to enhance the response of
Day-14 tumours. If ICRF-159 simply
enhanced the radiation response by re-
ducing tumour hypoxia, the response to
combined drug+radiation should have
been more effective on older tumours,
where the hypoxic fraction of cells is
greater. On the other hand, the enhance-
ment of the radiation response in 7-day
tumours suggests that the effect of the
drug on radiosensitivity may have its basis
in kinetic perturbation of tumour cells.
Taylor & Bleehen (1977a) have reported
greater sensitivity of EMT6 tumour cells
in exponential than in plateau-phase
culture to ICRF-159 plus radiation. The
effect in vitro is largely dependent on the
proportion of proliferating cells (growth
fraction) in the population. This observa-
tion obviously does not exclude an angio-
metamorphic effect in vivo.
Single acute doses of ICRF-159 were
ineffective in preventing growth ofthe LL
tumour (Fig. 3) when compared to daily
treatment at lower doses (Fig. 2), suggest-
ing that drug exposure time rather than
dose determines drug efficacy. Hellmann &
Field (1970) and Sharpe et al. (1970) have
reported that the cytotoxic effect ofICRF-
159 was limited to a very brief period
(G2/M) ofthe cell cycle, and that for short
incubations cell kill was independent of
dose. In addition to the cytotoxic effect,
ICRF-159 can act concomitantly as a
cytostatic agent, preventing cells from
entering mitosis (Hallowes et al., 1974;
Blackett & Adams, 1972). Recently,
Taylor & Bleehen (1977a) have shown
that the manifestations of cytotoxicity are
dependent on both drug exposure time
and drug concentration. While low con-
centrations were equally as effective as
high doses initially in terms of cell kill,
non-cytostatic concentrations (10 ,ug/ml)
produced progressive cell kill, but only
during prolonged drug exposure.
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Single injections of ICRF-159 (25-175
mg/kg) at the time of irradiation, unlike
daily pretreatment with the drug, failed to
potentiate the radiation response of LL
(Fig. 4). In fact, there is some evidence
that the drug "protected" against radia-
tion;regrowthofdrug+irradiation-treated
tumours began earlier than tumours
treated with radiation alone. Similar
differences have also been reported for the
radiosensitivity of cells in vitro after acute
(Hellmann & Murken, 1974) and protrac-
ted (Taylor & Bleehen, 1977a) pretreat-
ment with ICRF-159. Acute drug pre-
treatment failed to enhance the radio-
sensitivity of cells. Protracted drug expo-
sure, however, significantly decreased the
width of the shoulder of the radiation
survival curve provided that drug expo-
sure before irradiation was longer than
10 h. From their studies, Taylor and
Bleehen (1977b) concluded that ICRF-159
prevents cells from accumulating sub-
lethal damage rather than preventing the
repairofsuchdamage. Norpoth etal. (1974)
have reported that the carboxymethyl
cellulose (CMC) drug carrier protected the
Walker 256 carcinosarcoma against the
effects of radiation. Our studies (Fig. 5),
however, failed to demonstrate any pro-
tective effect of CMC on the radiation
response ofthe LL tumour.
It seems clear that fractionated pre-
treatment with ICRF-159 is better than
acute pretreatment for potentiating radio-
therapy. Whether this distinction results
from the maintenance of a threshold dose
over extended periods, or from a cumula-
tive dose, is at this point unknown. Also,
the mechanism of such potentiation ofthe
radiation effect is unknown, but most
probably is cytokinetic in nature. The
enhanced radiation response after frac-
tionated pretreatment could be the result
of either (1) a drug-induced redistribution
or synchrony at G2/M; (2) a reduced po-
tential for the accumulation and/or repair
of sublethal radiation damage; or (3) a
combination of (1) and (2).
Both daily and fractionated pretreat-
ments with ICRF-159 increased the effi-
cacy ofcombineddrug+radiation therapy.
Whether the mechanism responsible for
the enhancement is the same under both
pretreatment conditions is not clear. It is
likely that mechanisms other than vas-
cular normalization are operative in short
intervals after ICRF-159 administration.
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